3 results
Primary ObjectiveSafety Lead-in* Evaluate the safety of a high-dose regimen of encorafenib + binimetinib combination therapy in patients with BRAFV600-mutant melanoma who have asymptomatic brain metastasisPhase 2If the high-dose regimen is…
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Primary goal:The cure at 12 monthsSecondary goals:1. Cough Stress Test (HST): objective endpoint2. Question 3 of the UDI-6 questionnaire: subjective endpoint3. Primary endpoint at 6 weeks, 6 months, and 36 months 24maanden4. Reduction of urine loss…